

Table 1.16

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity  
Males, 18 SEER Areas, 2011-2013

Site	All Races		Whites		Blacks	
	Percent	( 95% C.I. )	Percent	( 95% C.I. )	Percent	( 95% C.I. )
All Sites	40.84	( 40.71, 40.96 )	40.52	( 40.39, 40.66 )	39.33	( 38.95, 39.72 )
Invasive and In Situ	42.33	( 42.21, 42.46 )	42.05	( 41.91, 42.19 )	39.64	( 39.26, 40.04 )
Oral Cavity and Pharynx	1.59	( 1.56, 1.61 )	1.66	( 1.64, 1.69 )	1.17	( 1.10, 1.23 )
Esophagus	0.78	( 0.76, 0.80 )	0.83	( 0.81, 0.85 )	0.61	( 0.56, 0.66 )
Stomach	1.05	( 1.03, 1.07 )	0.95	( 0.93, 0.97 )	1.20	( 1.13, 1.28 )
Colon and Rectum	4.56	( 4.52, 4.61 )	4.43	( 4.39, 4.48 )	4.77	( 4.64, 4.91 )
Invasive and In Situ	4.73	( 4.69, 4.78 )	4.59	( 4.54, 4.64 )	5.00	( 4.86, 5.14 )
Liver and Intrahepatic Bile Duct	1.35	( 1.33, 1.37 )	1.21	( 1.19, 1.23 )	1.48	( 1.42, 1.55 )
Pancreas	1.57	( 1.54, 1.59 )	1.57	( 1.54, 1.60 )	1.49	( 1.42, 1.58 )
Larynx	0.57	( 0.56, 0.58 )	0.57	( 0.56, 0.59 )	0.73	( 0.68, 0.79 )
Invasive and In Situ	0.61	( 0.60, 0.63 )	0.61	( 0.60, 0.63 )	0.77	( 0.72, 0.82 )
Lung and Bronchus	7.00	( 6.95, 7.05 )	6.99	( 6.94, 7.05 )	7.28	( 7.11, 7.46 )
Melanoma of the Skin	2.67	( 2.64, 2.71 )	3.10	( 3.07, 3.14 )	0.09	( 0.07, 0.12 )
Invasive and In Situ	4.49	( 4.45, 4.54 )	5.10	( 5.05, 5.15 )	0.12	( 0.09, 0.15 )
Breast	0.12	( 0.12, 0.13 )	0.12	( 0.12, 0.13 )	0.16	( 0.14, 0.19 )
Invasive and In Situ	0.14	( 0.13, 0.14 )	0.14	( 0.13, 0.14 )	0.18	( 0.16, 0.22 )
Prostate	12.88	( 12.81, 12.94 )	12.10	( 12.02, 12.17 )	17.02	( 16.78, 17.27 )
Testis	0.39	( 0.38, 0.40 )	0.46	( 0.45, 0.47 )	0.10	( 0.09, 0.12 )
Urinary Bladder (Invasive and In Situ)	3.78	( 3.74, 3.82 )	4.10	( 4.05, 4.14 )	1.84	( 1.75, 1.94 )
Kidney and Renal Pelvis	2.06	( 2.04, 2.09 )	2.12	( 2.09, 2.15 )	1.95	( 1.87, 2.03 )
Brain and Other Nervous System	0.69	( 0.68, 0.71 )	0.76	( 0.74, 0.78 )	0.40	( 0.37, 0.44 )
Thyroid	0.62	( 0.60, 0.63 )	0.65	( 0.64, 0.67 )	0.29	( 0.26, 0.32 )
Hodgkin Lymphoma	0.23	( 0.22, 0.24 )	0.24	( 0.23, 0.25 )	0.21	( 0.19, 0.24 )
Non-Hodgkin Lymphoma	2.36	( 2.33, 2.39 )	2.46	( 2.43, 2.49 )	1.38	( 1.31, 1.45 )
Myeloma	0.88	( 0.86, 0.90 )	0.82	( 0.80, 0.84 )	1.38	( 1.31, 1.46 )
Leukemia	1.77	( 1.74, 1.80 )	1.85	( 1.82, 1.88 )	1.18	( 1.12, 1.26 )
Acute Lymphocytic Leukemia	0.14	( 0.14, 0.15 )	0.16	( 0.15, 0.16 )	0.08	( 0.07, 0.10 )
Chronic Lymphocytic Leukemia	0.70	( 0.68, 0.72 )	0.74	( 0.72, 0.76 )	0.47	( 0.43, 0.52 )
Acute Myeloid Leukemia	0.54	( 0.53, 0.56 )	0.56	( 0.54, 0.58 )	0.39	( 0.35, 0.43 )
Chronic Myeloid Leukemia	0.23	( 0.22, 0.24 )	0.24	( 0.23, 0.25 )	0.15	( 0.13, 0.18 )
Kaposi Sarcoma	0.19	( 0.18, 0.20 )	0.21	( 0.20, 0.22 )	0.08	( 0.06, 0.10 )
Mesothelioma	0.07	( 0.07, 0.08 )	0.06	( 0.06, 0.07 )	0.15	( 0.14, 0.18 )

Devcan Version 6.7.4, August 2016, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG).

Note: Invasive cancer only unless specified otherwise.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.16 - continued

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity  
Males, 18 SEER Areas, 2011-2013

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives <sup>a</sup>	Hispanics <sup>b</sup>
	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )
All Sites	35.16 ( 34.66, 35.67 )	32.13 ( 30.40, 34.08 )	37.49 ( 37.03, 37.96 )
Invasive and In Situ	35.49 ( 34.99, 36.00 )	32.52 ( 30.77, 34.49 )	37.97 ( 37.51, 38.45 )
Oral Cavity and Pharynx	1.22 ( 1.13, 1.31 )	1.34 ( 1.05, 1.94 )	1.10 ( 1.03, 1.18 )
Esophagus	0.44 ( 0.39, 0.51 )	0.58 ( 0.37, 1.14 )	0.57 ( 0.52, 0.64 )
Stomach	1.97 ( 1.85, 2.10 )	1.48 ( 1.14, 2.13 )	1.57 ( 1.48, 1.69 )
Colon and Rectum	5.13 ( 4.94, 5.33 )	4.99 ( 4.33, 5.91 )	4.59 ( 4.43, 4.75 )
Invasive and In Situ	5.30 ( 5.11, 5.50 )	5.07 ( 4.41, 5.99 )	4.74 ( 4.58, 4.91 )
Liver and Intrahepatic Bile Duct	2.56 ( 2.44, 2.70 )	1.67 ( 1.39, 2.26 )	2.25 ( 2.15, 2.37 )
Pancreas	1.66 ( 1.56, 1.79 )	1.37 ( 0.96, 2.10 )	1.52 ( 1.42, 1.63 )
Larynx	0.29 ( 0.24, 0.34 )	0.34 ( 0.21, 0.87 )	0.51 ( 0.46, 0.58 )
Invasive and In Situ	0.33 ( 0.28, 0.40 )	0.37 ( 0.23, 0.89 )	0.55 ( 0.50, 0.62 )
Lung and Bronchus	6.79 ( 6.56, 7.03 )	6.30 ( 5.52, 7.34 )	4.67 ( 4.49, 4.86 )
Melanoma of the Skin	0.20 ( 0.17, 0.26 )	0.44 ( 0.30, 0.96 )	0.57 ( 0.51, 0.65 )
Invasive and In Situ	0.28 ( 0.24, 0.35 )	0.83 ( 0.59, 1.40 )	0.89 ( 0.81, 0.98 )
Breast	0.06 ( 0.04, 0.09 )	0.03 ( 0.01, 0.57 )	0.09 ( 0.06, 0.14 )
Invasive and In Situ	0.06 ( 0.05, 0.10 )	0.05 ( 0.01, 0.58 )	0.09 ( 0.07, 0.14 )
Prostate	8.63 ( 8.40, 8.87 )	6.65 ( 5.92, 7.64 )	11.95 ( 11.72, 12.20 )
Testis	0.15 ( 0.13, 0.18 )	0.35 ( 0.27, 0.84 )	0.35 ( 0.33, 0.39 )
Urinary Bladder (Invasive and In Situ)	2.36 ( 2.22, 2.52 )	1.89 ( 1.42, 2.68 )	2.56 ( 2.42, 2.72 )
Kidney and Renal Pelvis	1.44 ( 1.34, 1.54 )	2.61 ( 2.21, 3.29 )	2.19 ( 2.08, 2.31 )
Brain and Other Nervous System	0.44 ( 0.39, 0.50 )	0.48 ( 0.33, 1.01 )	0.57 ( 0.52, 0.63 )
Thyroid	0.67 ( 0.62, 0.73 )	0.34 ( 0.23, 0.84 )	0.49 ( 0.45, 0.54 )
Hodgkin Lymphoma	0.13 ( 0.11, 0.17 )	0.18 ( 0.08, 0.70 )	0.22 ( 0.19, 0.27 )
Non-Hodgkin Lymphoma	2.11 ( 1.99, 2.24 )	1.73 ( 1.29, 2.47 )	2.34 ( 2.23, 2.46 )
Myeloma	0.64 ( 0.58, 0.73 )	0.73 ( 0.48, 1.33 )	0.91 ( 0.84, 0.99 )
Leukemia	1.17 ( 1.08, 1.28 )	1.20 ( 0.91, 1.80 )	1.46 ( 1.36, 1.57 )
Acute Lymphocytic Leukemia	0.12 ( 0.10, 0.15 )	0.14 ( 0.08, 0.65 )	0.20 ( 0.18, 0.24 )
Chronic Lymphocytic Leukemia	0.22 ( 0.18, 0.28 )	0.26 ( 0.11, 0.81 )	0.37 ( 0.32, 0.45 )
Acute Myeloid Leukemia	0.55 ( 0.49, 0.62 )	0.38 ( 0.24, 0.91 )	0.51 ( 0.46, 0.59 )
Chronic Myeloid Leukemia	0.16 ( 0.14, 0.21 )	0.23 ( 0.12, 0.75 )	0.23 ( 0.19, 0.28 )
Kaposi Sarcoma	0.10 ( 0.07, 0.14 )	0.17 ( 0.07, 0.71 )	0.18 ( 0.15, 0.22 )
Mesothelioma	0.03 ( 0.02, 0.06 )	0.03 ( 0.00, 0.56 )	0.10 ( 0.08, 0.15 )

Devcan Version 6.7.4, August 2016, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG).

Note: Invasive cancer only unless specified otherwise.

<sup>a</sup> Underlying incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. A percent or confidence interval value of 0.00 represents a value that is below 0.005.